ESH CLL 2022 | Recent updates on TP53 mutation in CLL
Arnon Kater, MD, PhD, University of Amsterdam, Amsterdam, Netherlands, discusses the most recent updates on TP53 mutation in chronic lymphocytic leukemia (CLL), which was covered in one of his presentations at ESH CLL 2022. Dr Kater first highlights the poor outcome and low response to chemotherapy associated with patients who have TP53 or del(17p) mutation. Dr Kater then explains that these poor outcomes still need to be overcome despite the use of novel agents such as Bruton’s tyrosine kinase (BTK) and BCL-2 inhibitors. To conclude, Dr Kater mentions the need to better understand why TP53 mutation is a poor biomarker for disease, and how to improve techniques to measure this in the future. This interview took place during the 2nd ESH Translational Research Conference on Chronic Lymphocytic Leukemia (ESH CLL), 2022.
Disclosures
Research funding Abbvie, Gennetech, Janssen, AZ, BMS
